REVIEW

Duplex kidney formation: developmental mechanisms and genetic predisposition [version 1; peer review: 2 approved]

Vladimir M. Kozlov, Andreas Schedl

iBV, Institut de Biologie Valrose, Equipe Labellisée Ligue Contre le Cancer, Université Côte d'Azur, Centre de Biochimie, UFR Sciences, Parc Valrose, Nice Cedex 2, 06108, France

V1 First published: 06 Jan 2020, 9(F1000 Faculty Rev):2
<https://doi.org/10.12688/f1000research.19826.1>

Latest published: 06 Jan 2020, 9(F1000 Faculty Rev):2
<https://doi.org/10.12688/f1000research.19826.1>

Abstract

Congenital abnormalities of the kidney and urinary tract (CAKUT) are a highly diverse group of diseases that together belong to the most common abnormalities detected in the new-born child. Consistent with this diversity, CAKUT are caused by mutations in a large number of genes and present a wide spectrum of phenotypes. In this review, we will focus on duplex kidneys, a relatively frequent form of CAKUT that is often asymptomatic but predisposes to vesicoureteral reflux and hydronephrosis. We will summarise the molecular programs responsible for ureter induction, review the genes that have been identified as risk factors in duplex kidney formation and discuss molecular and cellular mechanisms that may lead to this malformation.

Keywords

CAKUT, kidney development, duplex systems, ureter budding

Open Peer Review

Approval Status

	1	2
version 1 06 Jan 2020		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Norman D. Rosenblum**, The Hospital for Sick Children, Toronto, Canada

2. **Satu Kuure**, University of Helsinki, Helsinki, Finland

Any comments on the article can be found at the end of the article.

Corresponding author: Andreas Schedl (schedl@unice.fr)

Author roles: Kozlov VM: Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Schedl A: Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the La Ligue Contre le Cancer.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Kozlov VM and Schedl A. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Kozlov VM and Schedl A. **Duplex kidney formation: developmental mechanisms and genetic predisposition [version 1; peer review: 2 approved]** F1000Research 2020, 9(F1000 Faculty Rev):2 <https://doi.org/10.12688/f1000research.19826.1>

First published: 06 Jan 2020, 9(F1000 Faculty Rev):2 <https://doi.org/10.12688/f1000research.19826.1>

Introduction

The urinary tract, composed of the kidneys, ureters, bladder and urethra, represents the main excretory system of the mammalian organism. Development of the urinary system, made up of more than 40 different cell types, needs to proceed in a highly organised manner. Given this complexity, it is not surprising that mutations in developmental genes can lead to a wide variety of abnormalities that are usually grouped together as congenital abnormalities of the kidneys and urinary tract (CAKUT). Defects affecting the kidneys range from renal agenesis (a complete lack of kidney development) to hypoplasia (reduced size), dysplasia (abnormally developed tissue), cystic dysplasia, and terminal differentiation defects. Lower urinary tract malformations include vesicoureteral reflux (VUR), hypospadias (opening of the urethra at the lower side of the penis) and posterior urethral valves that often lead to outflow obstructions. Although individual malformations are considered rare diseases, CAKUT, taken together, have an incidence of about 3 to 6 in 1000 live births and thus belong to the most frequent abnormalities detected in the new-born child¹. An in-depth presentation of all subclasses and their aetiology would be far beyond the scope of this review and therefore interested readers are referred to other publications that present an overview of CAKUT phenotypes and the genetics underlying them²⁻⁶. Here, we will instead concentrate on duplex (or multiplex) kidneys, a very frequent subclass of CAKUT, which is often neglected in the literature.

Development of the urinary system

To understand the aetiology of duplex kidneys, it is important to consider how the urinary system forms. From a developmental point of view, the urogenital tract derives from two independent germ layers with kidneys and ureters arising from the intermediate mesoderm (IM) and the bladder and urethra developing from cloacal endoderm⁷. Accordingly, malformations of the urinary system can be further classified into congenital abnormalities of the upper and lower urinary tract (and the latter are sometimes abbreviated as CALUT). Despite this developmental distinction, it should be noted that some authors group malformations of the ureter as part of congenital abnormalities of the lower urinary tract.

Kidney development in mammals commences with the formation of the nephric duct (ND) at the anterior (rostral) pole of the IM. As development proceeds, epithelial cells of the ND proliferate and actively migrate towards the caudal end of the nephrogenic cord⁸⁻¹⁰. Eventually, the ND fuses with the cloaca, a process that involves dedicated apoptosis and requires GATA3 and LHX1 as well as retinoic acid and RET and FGF signalling⁹⁻¹³.

As the ND elongates caudally, a series of tubules forms within the nephrogenic cord. The most anteriorly positioned pronephric tubules are considered an evolutionary remnant and are non-functional in mammals. Subsequently, a wave of mesonephric tubules develop that fall into two groups. While rostrally positioned tubules are connected to the ND and serve as an embryonic kidney, more caudally located tubules do not drain into the ND and are non-functional^{14,15}. Both pronephros

and mesonephros are transitory structures in the mammalian embryo and disappear (pronephros) or are remodelled (mesonephros) at later stages of development.

The metanephros represents the permanent kidney in mammals and develops at the most caudal position of the IM. Metanephros development is first detectable as a population of slightly condensed mesenchymal cells within the nephrogenic cord which express a set of molecular markers (*HOX11*, *SIX2*, *GDNF*, *EYA1*)^{15,16}. In normal development, signalling from the metanephric mesenchyme (MM) induces the formation and outgrowth of a single ureteric bud (UB) from the ND, which will invade the MM and undergo a first stereotypic dichotomous branching event (T-shaped ureter). The collecting duct system (ureteric tree) forms through further rounds of branching that often include tri-tips, which, however, eventually resolve into ureter bifurcations^{17,18}. In return, signals released from the ureter will induce the MM to differentiate into nephrons, the functional units of the kidney. For further details on this process, we refer the reader to recent reviews¹⁹⁻²².

Development of the urinary system is not restricted to kidney formation but also involves extensive developmental remodeling of the lower tract. An excellent and detailed description of this complex process can be found in 7. In brief, the emerging UB is initially connected to the cloaca via the distal part of the ND, also termed the common nephric duct (CND). Downgrowth of the urorectal septum leads to a separation of the cloaca into a ventrally located urogenital sinus and a dorsally positioned anorectal sinus^{7,23-25}. The cranial urogenital sinus will further elongate to develop into the bladder, whereas its posterior portion will form the urethra. As development proceeds, apoptosis eliminates the CND, leading to the fusion of the ureter with the future bladder, thus creating the ureterovesical junction²⁶.

Classification and epidemiology of duplex kidneys

Duplex systems can have a variety of phenotypes, and multiple classification systems have been proposed to categorise this pathology (Figure 1)²⁷. In incomplete duplication, the two poles of a duplex kidney share the same ureteral orifice of the bladder. Such duplex kidneys with a bifid pelvis or ureter arise when an initially single UB bifurcates before it reaches the ampulla. This is likely caused by a premature first branching event that occurred before the ureter has reached the MM. Much more frequent are complete duplications, which occur when two UBs emerge from the ND. In most cases, the lower pole of the kidney is normal and the upper pole is abnormal^{28,29}, an observation explained by the fact that the ectopic UB frequently emerges anteriorly to the position of the normal UB and drives the formation of the upper pole of a duplex kidney. Inverted Y-ureteral duplication is a rare condition in which two ureteral orifices drain from a single normal kidney. Inverted Y-ureteral duplication is believed to be caused by the merging of two independent UBs just before or as they reach the kidney anlagen³⁰. A very rare H-shaped ureter has also been reported³¹. Although the vast majority of cases involve a simple duplication, multiplex ureters with up to six independent buds have also been

described^{32–37}. In some cases, the additional ureter or ureters are ectopic and fail to connect to the bladder or the kidney (blind ending ureter)³³.

The aetiology of most duplex kidneys can be traced back to the very first induction steps of the ureter. In the majority of cases, an additional UB emerges in a rostral position to the normal outgrowth. By contrast, in adults, the upper (abnormal) kidney pole drains into the bladder at a site distal to the orifice of the lower kidney pole³⁸. This paradoxical phenomenon, known as the Weigert–Meyer rule²⁹, can be explained by the significant amount of remodelling occurring at the future ureter–bladder junction during development. Indeed, as apoptosis eliminates the CND, the ureter inserts into the developing bladder and moves upwards (Figure 2)^{7,39–41}. An initially anteriorly positioned ureter thus ends up with a more distal insertion site in the bladder, a model that has been proposed by

Mackie and Stephens⁴². Correct positioning of the ureter into the bladder is important to allow formation of a normal trigone (the triangle formed by the two ureter orifices and the urethra) and prevent ureter reflux caused by a malfunctioning valve or a too-short ureter tunnel. Because the vast majority of duplex kidneys arise from an ectopic bud in a rostral position, it is usually the upper pole of the kidney that is affected by VUR and hydronephrosis.

Estimates suggest a prevalence of duplex kidneys of between 0.2 and 2% in the general population, and females are affected twice as frequently as males^{38,43}. The reasons for this sex bias are unknown. About 40% of patients with duplex kidneys have been reported to exhibit pathological manifestations⁴³. However, because duplex kidneys are frequently asymptomatic and therefore predominantly detected in patients who seek medical assistance, the actual percentage of patients with symptoms is likely to be lower. Symptoms associated with duplex kidneys can include pain, haematuria, dysuria and difficulty or abnormal frequency of micturition^{38,43}. Specific manifestation of the pathology depends on the anatomy of each duplication event⁴⁴. Furthermore, duplex kidneys are linked to a number of renal disorders, including pelvi-calyceal dilatation, cortical scarring, VUR, hydronephrosis, ureteroceles on the non-duplex side, calculi or yo-yo reflux (in the incomplete duplication cases)^{38,43}.

Molecular pathways controlling ureter induction

If duplex kidney formation is rooted in the formation of two ureteric tips, how can we explain the outgrowth of supernumerary buds on a molecular level? Interactions between MM and the ND are crucial to ensure the induction of the ureter from the ND, and a key pathway controlling this process is the GDNF/RET signalling axis (Figure 3)⁴⁵. GDNF, a distant member of the transforming growth factor beta (TGFβ) superfamily of signalling molecules, is specifically expressed within the MM, whereas its cognate receptor RET is expressed along the entire length of the ND. Binding of GDNF to RET is greatly facilitated by the co-receptor GFRα1. The requirement for these genes in ureter outgrowth has been extensively demonstrated by using gene targeting in mice, and homozygous mutations in either of these genes leads to a failure of ureter induction and consequently renal agenesis^{46–50}. Binding of GDNF to the receptor tyrosine kinase RET induces autophosphorylation and recruitment of the

Figure 1. Classification of duplex kidney anatomy. Compared with a normal kidney (a), complete duplication produces a duplex kidney with two poles that drain into two ureters (b). Incomplete duplication leads to a Y-shaped ureter (c). Blind ureters do not drain into the bladder (d). In the rare case of inverted Y-ureteral duplication, two ureters fuse before entering the kidney (e).

Figure 2. Morphogenesis of duplex kidney. Duplex kidneys form through the induction of two ureteric buds from the nephric duct that will invade the metanephric mesenchyme. Subsequently, apoptosis of the common nephric duct (CND) leads to the insertion of both ureters into the developing bladder with the orifice of the initially posteriorly positioned ureteric bud ending up in a superior position.

Figure 3. Molecular interactions during kidney development. GDNF-RET signalling is at the core of the signalling network in kidney development and is responsible for ureteric bud (UB) emergence. GDNF expression is positively modulated by factors expressed in metanephric mesenchyme (PAX2, EYA1 and SALL1) and negatively (probably in an indirect manner) by SOX11, FOXC1, FOXC2 and ROBO2 in anterior domains of the nephrogenic cord. Ectopic formation of the UB is prevented by the factors expressed in nephric duct (SLIT2, SPRY1 and GATA3) and in the enveloping mesenchyme (BMP4 and FAT4). Influence from other upstream factors leads to the formation of a complex regulatory landscape.

tyrosine phosphatase SHP2^{51,52}, which results in the activation of several intracellular signalling cascades, including RAS/MAPK, PLCγ/Ca²⁺, PI3K-AKT⁵³, and culminates in the transcriptional activation of a set of downstream target genes⁵⁴. Ureter branching appears to involve, in particular, the ERK/MAPK pathway, and mice lacking the kinases *Mek1* and *Mek2* fail to form a properly branched ureteric tree⁵⁵. Activated RET signalling induces not only proliferation but also cellular motility. Indeed, experiments in chimeric mice demonstrated that wild-type cells move towards the tip of the UB but that *Ret* mutant cells are left behind⁵⁶. This cellular sorting mechanism ensures a strong and directed response that, under normal circumstances, results in the outgrowth of a single UB.

Factors regulating Gdnf expression

Given the crucial function of *Gdnf* in ureter induction, we need to consider how the expression of this gene is regulated. Activation of *Gdnf* in the mesenchyme relies on a set of transcription factors, including SALL1, PAX2 and EYA1. Deletion of either of these factors in mice leads to a lack of ureter induction and consequently to renal agenesis^{57–59}. Heterozygous mutations in each

of these genes have been shown to be involved in CAKUT^{5,6}, and SALL1, in particular, has also been linked to duplex kidney formation⁶⁰. In addition, *Gdnf* mRNA levels appear to be regulated post-transcriptionally via its 3' untranslated region (UTR). Indeed, replacement with a heterologous UTR sequence resulted in increased *Gdnf* expression levels that were associated with ND remodelling defects independent of apoptosis⁶¹.

In the mouse, *Gdnf* expression commences in rostral domains of the nephrogenic cord at embryonic day 9.5 (E9.5), about 1 day before ureter induction. The ND, however, does not respond to the GDNF signal in those anterior regions and this is likely to be due to two reasons: First, the anterior IM has relatively high levels of BMP signalling, which is known to suppress ureter branching (see the 'Restricting Ret activation' section below). Second, SLIT/ROBO signalling, a pathway that is known for its role in axon repulsion⁶², appears to repulse *Gdnf*-expressing cells from the ND, thus causing a physical separation of these two structures in anterior regions⁶³. *Robo2* knockout mice lack this separation and show ectopic buds along the entire length of the ND⁶⁴. The physical separation of ND and *Gdnf*-expressing cells may explain why in *Foxc1*, *Foxc2* and *Sox11* mouse mutants, which all display a dramatic expansion of *Gdnf* expression, the ND does not respond in the anterior domain^{64–66}. Instead, only the region just rostrally to the normal site of induction responds by forming a second ureter. Mutations in *ROBO2*, *SLIT2* and its associated GTPase-activating protein *SRGAP2* are found in patients with VUR and duplex systems^{67,68}.

By the time of ureter induction (E10.5 in mice), mesenchymal cells that express *Gdnf* become restricted to the caudal part of the MM (Figure 4). Three possible mechanisms for this restriction could be envisaged: (1) Active suppression of *Gdnf* expression in more rostral domains could occur. Since the expression of *Foxc1* and *Sox11* overlaps with the *Gdnf* domain, active suppression of the latter seems unlikely. (2) *Gdnf*-positive cells at the rostral end could undergo cell death. The pro- and mesonephros are known to be subject to massive apoptosis, although this seems to affect, in particular, the epithelial cells of tubules. However, preliminary data from our lab suggest that mesenchymal cells positioned just rostrally of the *Gdnf*-expressing domain also undergo apoptosis. (3) Finally, rostrally positioned *Gdnf*-positive cells may undergo directed migration towards the caudal end. The proposed distinct origin of ND and MM from the anterior and posterior IM, respectively, would argue against this possibility¹⁶. However, *Slit/Robo* signalling and members of the *SoxC* class genes have been implicated in cell migration^{62,69}. Perhaps *Gdnf* restriction is a combination of several mechanisms, including cell clearance through apoptosis and directed cell migration of anteriorly positioned *Gdnf*-positive cells. A careful analysis of mouse mutants showing an expansion of the *Gdnf* expression domain, perhaps coupled with live imaging in explant cultures, may help to address this open question.

Pathways in nephric duct-specific activation

PAX2 not only is involved in the activation of *GDNF* but also is required for the expression of ND-specific genes. A key target appears to be the transcription factor GATA3, which in

Figure 4. Possible causes of caudal *Gdnf* domain restriction. (a) At early stages during development, *Gdnf* expression can be found in rostral domains of the intermediate mesoderm but over time becomes caudally restricted. Three mechanisms could explain this observation: (b) active suppression of *Gdnf* expression in more rostral domains (c), apoptosis of *Gdnf*-expressing cells (d), or migration of the cells towards the caudal end of the intermediate mesoderm. E, embryonic day.

turn transcriptionally activates *Ret*. Tissue-specific knockout mice that lack *Gata3* within the ND show an altered response to local growth factors (GDNF and FGF) and display premature cell differentiation and differential cell adhesion properties. As a result, cells with sufficient levels of GATA3 and RET segregate from GATA3-deficient cells and expand, forming ectopic buds and kidneys⁷⁰.

Beta-catenin, a multifunctional protein involved in cell–cell adhesion and transcriptional regulation, appears to be one of the factors involved in this growth. Conditional inactivation of β -catenin in the ND leads to a range of kidney defects, including duplex kidney formation⁷¹. Molecular markers affected in these mutants were the transcription factors EMX2 and SOX9, both of which are known to be involved in ureter budding^{72,73}. However, ectopic budding was observed only in cases where loss of β -catenin expression was mosaic⁷⁴. Hypoxia-induced reduction of β -catenin has also been shown to cause duplex kidneys amongst other CAKUT phenotypes⁷⁵. Beta-catenin action during kidney induction is mediated at least partly through the transcription factor GATA3⁷⁰.

Sox17 mutations have been identified in a cohort of human patients with CAKUT, including a duplicated pyeloureteral system. The authors demonstrated that the mutation influenced protein stability and reduced β -catenin activity⁷⁶. It is therefore possible that the mutated SOX17 protein leads to lower β -catenin and, in turn, reduced GATA3 levels.

In parallel to GATA3, LHX1 (LIM1) appears to be essential in permitting normal budding⁷⁷. Tissue-specific deletion of LIM1 in ND derivatives leads to renal hypoplasia and hydronephrosis

and an impaired extension of the ND. Some conditional mutants of *Lim1* also display incomplete duplication of kidney ureters where both poles of a duplex kidney merge before entering the bladder. This form of duplex kidney was traced back to the first UB branching event, where defective UB forms a Y-shaped rather than a T-shaped structure⁹.

Restricting Ret activation

To limit ureter outgrowth to a single site, a series of negative regulators that suppress the RET signalling cascade are in place. BMP signalling, in particular, seems to be a suppressor of ureter outgrowth and branching, and heterozygous *Bmp4* mutations in mice lead to a wide range of CAKUT phenotypes, including duplex kidneys⁷⁸. BMP and FGF signalling are known antagonists in epithelial branching of the lung⁷⁹ but also kidney development⁸⁰. Since FGF and RET receptors are receptor tyrosine kinases that use similar intracellular signal transduction pathways, we can reason that the antagonistic action of BMP acts in analogous fashion on RET signalling. To permit ureter outgrowth specifically at the site of the future kidney, MM cells express the BMP inhibitor Gremlin (*Grem1*), which counteracts the BMP function⁸¹. Heterozygous *BMP4* and *GREM1* mutations have both been identified in human patients with CAKUT^{82,83}, although it is not clear whether variants in these genes also predispose to duplex kidney formation.

A number of other genes involved in duplex kidney formation appear to affect the BMP/Gremlin axis. Mutants for the intra-flagellar transport proteins IFT25 or IFT27, which are believed to increase GLI3R, a repressor of SHH signalling, show a high penetrance of duplex kidney formation (~50%)⁸⁴. Similarly, constitutive expression of a truncation mutation in *Gli3* (*Gli3* ^{Δ 699}),

which is found in Pallister–Hall syndrome and is likely to sensitise tissue for SHH signalling, causes CAKUT with duplex kidneys⁸⁵. The phenotype has been linked to an increased sensitivity of the ND by lowering BMP4 signalling.

Of interest, several genes that are implicated in the formation of cilia (for example, *Cep290*, *Dync2h1*, *Tbc1d32* and *Tmem67*) have also been implicated in duplex kidney formation⁸⁶. The primary cilia is an organelle that has a key function in cellular signalling⁸⁷, and SHH signalling, in particular, is directly linked to this organelle. Because SHH signalling has been proposed to be involved in duplex kidney formation (88 and above), it is tempting to speculate that the above cilia-related genes also influence this pathway.

In addition to extracellular modulators, cytoplasmic antagonists exist to suppress ureter outgrowth. Most notably, Sprouty (*Spry1*) suppresses MAPK signalling in the absence of GDNF, and inactivation in mice results in the formation of multiple UBs⁸⁹. Signalling through the angiotensin receptor appears to be important in suppressing *Spry1* expression⁹⁰ but also in activating *Ret* expression, and *Agtr2* knockout mice show a range of CAKUT phenotypes, including a duplex system⁹¹. To date, no pathogenetic *SPRY1* mutations have been identified in patients with CAKUT, and it is currently unclear to what extent this gene contributes to duplex kidney formation in human patients. Interestingly, in the absence of *Spry1*, GDNF signalling

is no longer required for ureter induction, and *Spry1^{-/-}/Gdnf^{-/-}* double knockout mice develop normal kidneys. In this context, FGF10, which normally plays only a minor role in kidney development, becomes indispensable for kidney induction, and triple mutants (*Fgf10^{-/-}/Spry1^{-/-}/Gdnf^{-/-}*) display renal agenesis⁹². FGF signalling thus can be considered a reinforcing signal that contributes to enhanced epithelial growth and budding. FGF signalling serves as the main pathway in branching morphogenesis of other organs such as the lung⁹³, and we can speculate that GDNF/RET signalling has taken over the ancestral function of FGF in epithelial branching of the kidney.

Finally, tissue-specific knockout of *Fat4* within the nephrogenic cord results in a duplex kidney phenotype that can be rescued by reducing the dose of GDNF (*Gdnf^{+/2}*). Recent molecular experiments demonstrated that FAT4 directly binds to RET and restricts its activity in the ND/UB by disrupting the formation of RET-GFRA1-GDNF complex^{94,95}.

There are a number of other genes which have been shown to be implicated in duplex kidney formation but for which the molecular events leading to supernumerary buds are not well defined. Because in these cases the causative nature of mutations for duplex kidney formation is less established, we refrain from a mere listing of genes at this place. The interested reader is referred to Table 1 of genes involved, the associated phenotypes and corresponding references.

Table 1. Genes involved in duplex kidney formation.

Group	Genotype	Mechanism	Reference
GDNF domain			
	<i>Robo2^{-/-}</i>	Abnormal <i>Gdnf</i> expression domain MM fails to separate from WD	Grieshammer <i>et al.</i> ⁶⁴ Wainwright <i>et al.</i> ⁶³
	<i>Slit2^{-/-}</i>	Abnormal <i>Gdnf</i> expression domain	Grieshammer <i>et al.</i> ⁶⁴
	<i>Foxc1^{-/-}</i>	MM fails to reduce in size	Kume <i>et al.</i> ⁶⁵ Komaki <i>et al.</i> ⁹⁶
	<i>Sox11^{-/-}</i>	MM fails to reduce in size	Neirijnck <i>et al.</i> ⁶⁶
Increased sensitivity of WD			
	<i>Bmp4^{+/-}</i>	Lack of inhibition of WNT11, a target of GDNF	Miyazaki <i>et al.</i> ⁷⁸ Michos <i>et al.</i> ⁸¹
	<i>lft25^{-/-}, lft27^{-/-}</i>	Increased sensitivity of WD through Gremlin-BMP4 cascade	Desai <i>et al.</i> ⁸⁴
	<i>Gli3^{Δ699/Δ699}</i>	Increased sensitivity of WD through Gremlin-BMP4 cascade	Blake <i>et al.</i> ⁸⁵
	<i>Agtr2^{-/-}</i>	Disrupted renin-angiotensin signalling leads to aberrant UB morphogenesis	Nishimura <i>et al.</i> ⁹¹ Yosypiv <i>et al.</i> ⁹⁰
	<i>p53^{-/-}, p53^{UB-/-}</i>	Increased response of WD to GDNF signal. Two ureters fuse in the later development and resemble a bifurcation	Saifudeen <i>et al.</i> ⁹⁷ El-dahr <i>et al.</i> ⁹⁸
	<i>Fat4^{-/-} Fjx1^{-/-}</i>	Premature branching with incomplete duplication due to overactive GDNF-RET signalling	Saburi <i>et al.</i> ⁹⁴ Zhang <i>et al.</i> ⁹⁵

Group	Genotype	Mechanism	Reference
	<i>Hoxb7-Cre</i> β -catenin ^{lc}	Ectopic activation of UB branching pathway in WD	Marose <i>et al.</i> ⁷⁴
	<i>Spry1</i> ^{-/-}	Increased sensitivity of WD to GDNF-RET signalling	Basson <i>et al.</i> ⁹⁹
	<i>Gata3</i> ND ^{-/-}	The entire length on WD is covered by ectopic UBs, most of which subsequently regress	Grote <i>et al.</i> ⁷⁰
Cell polarity defect			
	<i>T-Cre Wnt5a</i> ^{fΔ}	Double UB, abnormal morphology of posterior WD, defects in IM morphogenesis	Yun <i>et al.</i> ⁹⁹
	<i>Ror2</i> ^{-/-}	Similar to <i>Wnt5a</i> phenotype	Yun <i>et al.</i> ⁹⁹
Cell adhesion defect			
	<i>L1</i> ^{-/-}	Either incomplete or complete duplication. Double UB on WD or accessory budding from the main ureter	Debiec <i>et al.</i> ¹⁰⁰
Unknown			
	<i>Pax2</i> ^{+/-}	Premature branching with incomplete duplication, linked with inactivation of GDNF expression	Brophy <i>et al.</i> ¹⁰¹
	<i>Pax2-Cre Lim1</i> ^{$\Delta\Delta$}	WD fails to extend caudally; UB is absent or Y-shaped	Pedersen <i>et al.</i> ⁹
	<i>Cc2d2a</i> , <i>Mks1</i> , <i>Cep290</i> , <i>Dync2h1</i> , <i>Tbc1d32</i> , <i>Tmem67</i>	Duplex kidney as a part of a ciliopathy phenotype	San agustin <i>et al.</i> ⁸⁶
	<i>Sox17</i> ^{Y259N/+}	Duplicated pyeloureteral collecting system	Gimelli <i>et al.</i> ⁷⁶
	<i>Nfia</i> ^{-/-}	Partial ureteral duplication	Lu <i>et al.</i> ¹⁰²
	<i>Adams18</i> ^{-/-}	Complete ureteral duplication, increased nephron endowment	Rutledge <i>et al.</i> ¹⁰³

Conclusions and perspectives

As we have seen, the seemingly simple event of ureteric budding is a highly complicated and stringently controlled process that employs both positive and negative feedback loops. As such, the fact that a large number of genes are involved in duplex kidney formation is not surprising, and future analyses are likely to identify many more factors involved in these abnormalities. However, the incomplete penetrance of phenotypes and the multigenic basis of this malformation make the confirmation of mutations as being disease-causing increasingly difficult. Indeed, our own unpublished data suggest that duplex kidney phenotypes can be highly genetic background-dependent, indicating the presence of modifier genes. Moreover, intergenic/regulatory mutations or epigenetic mechanisms that

affect gene expression levels rather than protein function are likely to contribute to disease. Finally, we should keep in mind that, despite a large degree of conservation, mice and humans show significant differences on a developmental and molecular level^{104–106}. Findings in knockout mice are therefore only indicative and should not be directly extrapolated to human patients. Future research should also address the disparity in the frequency of duplex kidneys occurring in men and women. In the long run, the integration of a large amount of whole genome sequencing data coupled with a better understanding of how gene regulation is achieved will be required to corroborate the involvement of genomic changes and predict the phenotypic outcome in duplex kidneys.

References

1. Queisser-Luft A, Stolz G, Wiesel A, *et al.*: **Malformations in newborn: results based on 30,940 infants and fetuses from the Mainz congenital birth defect monitoring system (1990-1998).** *Arch Gynecol Obstet.* 2002; **266**(3): 163–7. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Capone VP, Morello W, Taroni F, *et al.*: **Genetics of Congenital Anomalies of the Kidney and Urinary Tract: The Current State of Play.** *Int J Mol Sci.* 2017; **18**(4): pii: E796. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

3. **F** Jain S, Chen F: **Developmental pathology of congenital kidney and urinary tract anomalies.** *Clin Kidney J.* 2018; **12**(3): 382–99.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
4. Schedl A: **Renal abnormalities and their developmental origin.** *Nat Rev Genet.* 2007; **8**(10): 791–802.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Nicolaou N, Renkema KY, Bongers EM, *et al.*: **Genetic, environmental, and epigenetic factors involved in CAKUT.** *Nat Rev Nephrol.* 2015; **11**(12): 720–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. **F** van der Ven AT, Vivante A, Hildebrandt F: **Novel Insights into the Pathogenesis of Monogenic Congenital Anomalies of the Kidney and Urinary Tract.** *J Am Soc Nephrol.* 2018; **29**(1): 36–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
7. **F** Georgas KM, Armstrong J, Keast JR, *et al.*: **An illustrated anatomical ontology of the developing mouse lower urogenital tract.** *Development.* 2015; **142**(10): 1893–908.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
8. **F** Grote D, Souabni A, Busslinger M, *et al.*: **Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney.** *Development.* 2006; **133**(1): 53–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
9. Pedersen A, Skjong C, Shawlot W: **Lim 1 is required for nephric duct extension and ureteric bud morphogenesis.** *Dev Biol.* 2005; **288**(2): 571–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Attia L, Schneider J, Yelin R, *et al.*: **Collective cell migration of the nephric duct requires FGF signaling.** *Dev Dyn.* 2015; **244**(2): 157–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Walker KA, Sims-Lucas S, Di Giovanni VE, *et al.*: **Deletion of fibroblast growth factor receptor 2 from the peri-wolffian duct stroma leads to ureteric induction abnormalities and vesicoureteral reflux.** *PLoS One.* 2013; **8**(2): e56062.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Chia I, Grote D, Marcotte M, *et al.*: **Nephric duct insertion is a crucial step in urinary tract maturation that is regulated by a Gata3-Raldh2-Ret molecular network in mice.** *Development.* 2011; **138**(10): 2089–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. **F** Hoshi M, Reginensi A, Joens MS, *et al.*: **Reciprocal Spatiotemporally Controlled Apoptosis Regulates Wolffian Duct Cloaca Fusion.** *J Am Soc Nephrol.* 2018; **29**(3): 775–783.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
14. Sainio K, Hellstedt P, Kreidberg JA, *et al.*: **Differential regulation of two sets of mesonephric tubules by WT-1.** *Development.* 1997; **124**(7): 1293–9.
[PubMed Abstract](#)
15. Mugford JW, Sipilä P, Kobayashi A, *et al.*: **Hoxd11 specifies a program of metanephric kidney development within the intermediate mesoderm of the mouse embryo.** *Dev Biol.* 2008; **319**(2): 396–405.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. **F** Taguchi A, Kaku Y, Ohmori T, *et al.*: **Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells.** *Cell Stem Cell.* 2014; **14**(1): 53–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
17. **F** Lefevre JG, Short KM, Lamberton TO, *et al.*: **Branching morphogenesis in the developing kidney is governed by rules that pattern the ureteric tree.** *Development.* 2017; **144**(23): 4377–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
18. Short KM, Combes AN, Lefevre J, *et al.*: **Global quantification of tissue dynamics in the developing mouse kidney.** *Dev Cell.* 2014; **29**(2): 188–202.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. McMahon AP: **Development of the Mammalian Kidney.** *Curr Top Dev Biol.* 2016; **117**: 31–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. **F** O'Brien LL: **Nephron progenitor cell commitment: Striking the right balance.** *Semin Cell Dev Biol.* 2019; **91**: 94–103.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
21. **F** Kurtzeborn K, Cebrian C, Kuure S: **Regulation of Renal Differentiation by Trophic Factors.** *Front Physiol.* 2018; **9**: 1588.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
22. **F** Oxburgh L: **Kidney Nephron Determination.** *Annu Rev Cell Dev Biol.* 2018; **34**: 427–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
23. Huang YC, Chen F, Li X: **Clarification of mammalian cloacal morphogenesis using high-resolution episcopic microscopy.** *Dev Biol.* 2016; **409**(1): 106–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Matsumaru D, Murashima A, Fukushima J, *et al.*: **Systematic stereoscopic analyses for cloacal development: The origin of anorectal malformations.** *Sci Rep.* 2015; **5**: 13943.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. **F** Kruepunga N, Hikspoors JPJM, Mekonen HK, *et al.*: **The development of the cloaca in the human embryo.** *J Anat.* 2018; **233**(6): 724–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
26. **F** Liaw A, Cunha GR, Shen J, *et al.*: **Development of the human bladder and ureterovesical junction.** *Differentiation.* 2018; **103**: 66–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
27. Glassberg KI, Braren V, Duckett JW, *et al.*: **Suggested Terminology for Duplex Systems, Ectopic Ureters and Ureterocele.** *J Urol.* 1984; **132**(6): 1153–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Zissin R, Apter S, Yaffe D, *et al.*: **Renal duplication with associated complications in adults: CT findings in 26 cases.** *Clin Radiol.* 2001; **56**(1): 58–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Weigert C: **Ueber einige Bildungsfehler der Ureteren.** *Virchows Arch.* 1877; **70**(4): 490–501.
[Publisher Full Text](#)
30. Britt DB, Borden TA, Woodhead DM: **Inverted Y Ureteral Duplication with a Blind-Ending Branch.** *J Urol.* 1972; **108**(3): 387–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Akbulut F, Savun M, Ucpinar B, *et al.*: **Duplicated Renal System with H Shaped Ureter: An Extraordinary Anomaly.** *Case Rep Urol.* 2016; **2016**: 4062515.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Begg RC: **Sextuplicitas Renum: A Case of Six Functioning Kidneys and Ureters in an Adult Female.** *J Urol.* 1953; **70**(5): 686–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Senel U, Tanriverdi HI, Ozmen Z, *et al.*: **Ectopic Ureter Accompanied by Duplicated Ureter: Three Cases.** *J Clin Diagn Res.* 2015; **9**(9): PD10–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Lopes RI, Lopes RN, Filho CMB: **Ureteral quadruplication with contralateral triplicate ureter.** *J Urol.* 2001; **166**(3): 979–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Kudela G, Koszowski T, Mikosinski M, *et al.*: **Ureteral triplication--report of four cases.** *Eur J Pediatr Surg.* 2006; **16**(4): 279–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Bolker M, Moskovitz B, Ginesin Y, *et al.*: **Incomplete quadruplication of urinary tract with contralateral agenesis of the kidney.** *Eur Urol.* 1991; **19**(3): 267–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Jurkiewicz B, Ząbkowski T, Shevchuk D: **Ureteral quintuplication with renal atrophy in an infant after the 1986 Chernobyl nuclear disaster.** *Urology.* 2014; **83**(1): 211–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Privett JTJ, Jeans WD, Roylance J: **The incidence and importance of renal duplication.** *Clin Radiol.* 1976; **27**(4): 521–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. **F** Batourina E, Choi C, Paragas N, *et al.*: **Distal ureter morphogenesis depends on epithelial cell remodeling mediated by vitamin A and Ret.** *Nat Genet.* 2002; **32**(1): 109–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. **F** Uetani N, Bertozzi K, Chagnon MJ, *et al.*: **Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.** *J Clin Invest.* 2009; **119**(4): 924–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
41. **F** Batourina E, Tsai S, Lambert S, *et al.*: **Apoptosis induced by vitamin A signaling is crucial for connecting the ureters to the bladder.** *Nat Genet.* 2005; **37**(10): 1082–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
42. Mackie GG, Stephens FD: **Duplex kidneys: a correlation of renal dysplasia with position of the ureteral orifice.** *J Urol.* 1975; **114**(2): 274–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Doery AJ, Ang E, Ditchfield MR: **Duplex kidney: not just a drooping lily.** *J Med Imaging Radiat Oncol.* 2015; **59**(2): 149–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. **F** Didier RA, Chow JS, Kwatra NS, *et al.*: **The duplicated collecting system of the urinary tract: embryology, imaging appearances and clinical considerations.** *Pediatr Radiol.* 2017; **47**(11): 1526–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
45. Davis TK, Hoshi M, Jain S: **To bud or not to bud: the RET perspective in CAKUT.** *Pediatr Nephrol.* 2014; **29**(4): 597–608.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Schuchardt A, D'Agati V, Larsson-Blomberg L, *et al.*: **Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret.** *Nature.* 1994; **367**(6461): 380–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Sánchez MP, Silos-Santiago I, Frisén J, *et al.*: **Renal agenesis and the absence of enteric neurons in mice lacking GDNF.** *Nature.* 1996; **382**(6586): 70–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Pichel JG, Shen L, Sheng HZ, *et al.*: **Defects in enteric innervation and kidney development in mice lacking GDNF.** *Nature.* 1996; **382**(6586): 73–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Moore MW, Klein RD, Fariñas I, *et al.*: **Renal and neuronal abnormalities in mice lacking GDNF.** *Nature.* 1996; **382**(6586): 76–9.
[PubMed Abstract](#) | [Publisher Full Text](#)

50. Cacalano G, Fariñas I, Wang LC, *et al.*: **GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney.** *Neuron*. 1998; 21(1): 53–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Willecke R, Heuberger J, Grossmann K, *et al.*: **The tyrosine phosphatase Shp2 acts downstream of GDNF/Ret in branching morphogenesis of the developing mouse kidney.** *Dev Biol*. 2011; 360(2): 310–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Perrinquet M, Vilar M, Ibáñez CF: **Protein-tyrosine phosphatase SHP2 contributes to GDNF neurotrophic activity through direct binding to phospho-Tyr⁸⁶⁷ in the RET receptor tyrosine kinase.** *J Biol Chem*. 2010; 285(41): 31867–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Takahashi M: **The GDNF/RET signaling pathway and human diseases.** *Cytokine Growth Factor Rev*. 2001; 12(4): 361–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. **F** Lu BC, Cebrian C, Chi X, *et al.*: **Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis.** *Nat Genet*. 2009; 41(12): 1295–302.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
55. Ihermann-Hella A, Lume M, Mäkeläinen J, *et al.*: **Mitogen-activated protein kinase (MAPK) pathway regulates branching by remodeling epithelial cell adhesion.** *PLoS Genet*. 2014; 10(3): e1004193.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. **F** Chi X, Michos O, Shakya R, *et al.*: **Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesis.** *Dev Cell*. 2009; 17(2): 199–209.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
57. Torres M, Gómez-Pardo E, Dressler GR, *et al.*: **Pax-2 controls multiple steps of urogenital development.** *Development*. 1995; 121(12): 4057–65.
[PubMed Abstract](#)
58. Kiefer SM, Robbins L, Stumpff KM, *et al.*: **Sall1-dependent signals affect Wnt signaling and ureter tip fate to initiate kidney development.** *Development*. 2010; 137(18): 3099–106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Xu PX, Adams J, Peters H, *et al.*: **Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia.** *Nat Genet*. 1999; 23(1): 113–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Hwang DY, Dworschak GC, Kohl S, *et al.*: **Mutations in 12 known dominant disease-causing genes clarify many congenital anomalies of the kidney and urinary tract.** *Kidney Int*. 2014; 85(6): 1429–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. **F** Li H, Jakobson M, Ola R, *et al.*: **Development of the urogenital system is regulated via the 3'UTR of GDNF.** *Sci Rep*. 2019; 9(1): 5302.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
62. Blockus H, Chédotal A: **Slit-Robo signaling.** *Development*. 2016; 143(17): 3037–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Wainwright EN, Wilhelm D, Combes AN, *et al.*: **ROBO2 restricts the nephrogenic field and regulates Wolffian duct-nephrogenic cord separation.** *Dev Biol*. 2015; 404(2): 88–102.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Grieshammer U, Le Ma, Plump AS, *et al.*: **SLIT2-mediated ROBO2 signaling restricts kidney induction to a single site.** *Dev Cell*. 2004; 6(5): 709–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Kume T, Deng K, Hogan BL: **Murine forkhead/winged helix genes Foxc1 (Mf1) and Foxc2 (Mfh1) are required for the early organogenesis of the kidney and urinary tract.** *Development*. 2000; 127(7): 1387–95.
[PubMed Abstract](#)
66. Neirijnck Y, Reginensi A, Renkema KY, *et al.*: **Sox11 gene disruption causes congenital anomalies of the kidney and urinary tract (CAKUT).** *Kidney Int*. 2018; 93(5): 1142–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Lu W, van Eerde AM, Fan X, *et al.*: **Disruption of ROBO2 is associated with urinary tract anomalies and confers risk of vesicoureteral reflux.** *Am J Hum Genet*. 2007; 80(4): 616–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Hwang DY, Kohl S, Fan X, *et al.*: **Mutations of the SLIT2-ROBO2 pathway genes SLIT2 and SRGAP1 confer risk for congenital anomalies of the kidney and urinary tract.** *Hum Genet*. 2015; 134(8): 905–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. **F** Cheng Q, Wu J, Zhang Y, *et al.*: **SOX4 promotes melanoma cell migration and invasion through the activation of the NF- κ B signaling pathway.** *Int J Mol Med*. 2017; 40(2): 447–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
70. Grote D, Bouallia SK, Souabni A, *et al.*: **Gata3 acts downstream of beta-catenin signaling to prevent ectopic metanephric kidney induction.** *PLoS Genet*. 2008; 4(12): e1000316.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Bridgewater D, Cox B, Cain J, *et al.*: **Canonical WNT/beta-catenin signaling is required for ureteric branching.** *Dev Biol*. 2008; 317(1): 83–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Miyamoto N, Yoshida M, Kuratani S, *et al.*: **Defects of urogenital development in mice lacking Emx2.** *Development*. 1997; 124(9): 1653–64.
[PubMed Abstract](#)
73. **F** Reginensi A, Clarkson M, Neirijnck Y, *et al.*: **SOX9 controls epithelial branching by activating RET effector genes during kidney development.** *Hum Mol Genet*. 2011; 20(6): 1143–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
74. Marose TD, Merkel CE, McMahon AP, *et al.*: **Beta-catenin is necessary to keep cells of ureteric bud/Wolffian duct epithelium in a precursor state.** *Dev Biol*. 2008; 314(1): 112–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Wilkinson LJ, Neal CS, Singh RR, *et al.*: **Renal developmental defects resulting from in utero hypoxia are associated with suppression of ureteric β -catenin signaling.** *Kidney Int*. 2015; 87(5): 975–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Gimelli S, Caridi G, Beri S, *et al.*: **Mutations in SOX17 are associated with congenital anomalies of the kidney and the urinary tract.** *Hum Mutat*. 2010; 31(12): 1352–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. **F** Kobayashi A, Kwan KM, Carroll TJ, *et al.*: **Distinct and sequential tissue-specific activities of the LIM-class homeobox gene Lim1 for tubular morphogenesis during kidney development.** *Development*. 2005; 132(12): 2809–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
78. Miyazaki Y, Oshima K, Fogo A, *et al.*: **Bone morphogenetic protein 4 regulates the budding site and elongation of the mouse ureter.** *J Clin Invest*. 2000; 105(7): 863–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. Weaver M, Dunn NR, Hogan BL: **Bmp4 and Fgf10 play opposing roles during lung bud morphogenesis.** *Development*. 2000; 127(12): 2695–704.
[PubMed Abstract](#)
80. Motamedi FJ, Badro DA, Clarkson M, *et al.*: **WT1 controls antagonistic FGF and BMP-pSMAD pathways in early renal progenitors.** *Nat Commun*. 2014; 5: 4444.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. Michos O, Gonçalves A, Lopez-Rios J, *et al.*: **Reduction of BMP4 activity by gremlin 1 enables ureteric bud outgrowth and GDNF/WNT11 feedback signalling during kidney branching morphogenesis.** *Development*. 2007; 134(13): 2397–405.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Weber S, Taylor JC, Winyard P, *et al.*: **SIX2 and BMP4 Mutations Associate With Anomalous Kidney Development.** *J Am Soc Nephrol*. 2008; 19(5): 891–903.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. van Eerde AM, Duran K, van Riel E, *et al.*: **Genes in the Ureteric Budding Pathway: Association Study on Vesico-Ureteral Reflux Patients.** *PLoS One*. 2012; 7(4): e31327.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. **F** Desai PB, San Agustín JT, Stuck MW, *et al.*: **lft25 is not a cystic kidney disease gene but is required for early steps of kidney development.** *Mech Dev*. 2018; 151: 10–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
85. **F** Blake J, Di Hu, Cain JE, *et al.*: **Urogenital development in Pallister-Hall syndrome is disrupted in a cell-lineage-specific manner by constitutive expression of GLI3 repressor.** *Hum Mol Genet*. 2016; 25(3): 437–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
86. **F** San Agustín JT, Klena N, Granath K, *et al.*: **Genetic link between renal birth defects and congenital heart disease.** *Nat Commun*. 2016; 7: 11103.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
87. Elliott KH, Bruggmann SA: **Sending mixed signals: Cilia-dependent signaling during development and disease.** *Dev Biol*. 2019; 447(1): 28–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Weber S, Landwehr C, Renkert M, *et al.*: **Mapping candidate regions and genes for congenital anomalies of the kidneys and urinary tract (CAKUT) by array-based comparative genomic hybridization.** *Nephrol Dial Transplant*. 2011; 26(1): 136–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
89. **F** Basson MA, Akbulut S, Watson-Johnson J, *et al.*: **Sprouty1 Is a Critical Regulator of GDNF/RET-Mediated Kidney Induction.** *Dev Cell*. 2005; 8(2): 229–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
90. Yosypiv IV, Boh MK, Spera MA, *et al.*: **Downregulation of Spry-1, an inhibitor of GDNF/Ret, causes angiotensin II-induced ureteric bud branching.** *Kidney Int*. 2008; 74(10): 1287–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. Nishimura H, Yerkes E, Hohenfellner K, *et al.*: **Role of the Angiotensin Type 2 Receptor Gene in Congenital Anomalies of the Kidney and Urinary Tract, CAKUT, of Mice and Men.** *Mol Cell*. 1999; 3(1): 1–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
92. **F** Michos O, Cebrian C, Hyink D, *et al.*: **Kidney development in the absence of Gdnf and Spry1 requires Fgf10.** *PLoS Genet*. 2010; 6(1): e1000809.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
93. Morrissey EE, Hogan BLM: **Preparing for the First Breath: Genetic and Cellular Mechanisms in Lung Development.** *Dev Cell*. 2010; 18(1): 8–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

94. **F** Saburi S, Hester I, Fischer E, *et al.*: **Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease.** *Nat Genet.* 2008; 40(8): 1010–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
95. **F** Zhang H, Bagherie-Lachidan M, Badouel C, *et al.*: **FAT4 Fine-Tunes Kidney Development by Regulating RET Signaling.** *Dev Cell.* 2019; 48(6): 780–792.e4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
96. Komaki F, Miyazaki Y, Niimura F, *et al.*: **Foxc1 gene null mutation causes ectopic budding and kidney hypoplasia but not dysplasia.** *Cells Tissues Organs.* 2013; 198(1): 22–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Saifudeen Z, Dipp S, Stefkova J, *et al.*: **p53 regulates metanephric development.** *J Am Soc Nephrol.* 2009; 20(11): 2328–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. El-Dahr S, Hilliard S, Aboudehen K, *et al.*: **The MDM2-p53 pathway: Multiple roles in kidney development.** *Pediatr Nephrol.* 2014; 29(4): 621–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. Yun K, Ajima R, Sharma N, *et al.*: **Non-canonical Wnt5a/Ror2 signaling regulates kidney morphogenesis by controlling intermediate mesoderm extension.** *Hum Mol Genet.* 2014; 23(25): 6807–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
100. Debiec H, Kutsche M, Schachner M, *et al.*: **Abnormal renal phenotype in L1 knockout mice: A novel cause of CAKUT.** *Nephrol Dial Transplant.* 2002; 17 Suppl 9: 42–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
101. **F** Brophy PD, Ostrom L, Lang KM, *et al.*: **Regulation of ureteric bud outgrowth by Pax2-dependent activation of the glial derived neurotrophic factor gene.** *Development.* 2001; 128(23): 4747–56.
[PubMed Abstract](#) | [F1000 Recommendation](#)
102. Lu W, Quintero-Rivera F, Fan Y, *et al.*: **NFIA haploinsufficiency is associated with a CNS malformation syndrome and urinary tract defects.** *PLoS Genet.* 2007; 3(5): e80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
103. **F** Rutledge EA, Parvez RK, Short KM, *et al.*: **Morphogenesis of the kidney and lung requires branch-tip directed activity of the Adamts18 metalloprotease.** *Dev Biol.* 2019; 454(2): 156–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
104. **F** Lindström NO, Guo J, Kim AD, *et al.*: **Conserved and Divergent Features of Mesenchymal Progenitor Cell Types within the Cortical Nephrogenic Niche of the Human and Mouse Kidney.** *J Am Soc Nephrol.* 2018; 29(3): 806–824.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
105. **F** Lindström NO, McMahon JA, Guo J, *et al.*: **Conserved and Divergent Features of Human and Mouse Kidney Organogenesis.** *J Am Soc Nephrol.* 2018; 29(3): 785–805.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
106. **F** Lindström NO, Tran T, Guo J, *et al.*: **Conserved and Divergent Molecular and Anatomic Features of Human and Mouse Nephron Patterning.** *J Am Soc Nephrol.* 2018; 29(3): 825–840.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Satu Kuure

Helsinki Institute of Life Science / STEMM Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Competing Interests: No competing interests were disclosed.

2. Norman D. Rosenblum

Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research